毛细管生物医学
成立一年
2014年阶段
收购了 |收购总了
4.75美元与毛细管生物医学吗?
确保你的公司和产品准确地代表在我们的平台上。
研究包含毛细管生物医学
获得CB的数据驱动的专家分析见解信息部。德赢体育vwin官方网站
德赢体育vwin官方网站情报分析家提到毛细管生物医学CB见解1 德赢体育vwin官方网站CB见解研究短暂,最近在2022年10月28日。
2022年10月28日
拆分糖尿病:科技是如何改变这种疾病的护理和管理集合包含毛细管生物医学专家
专家集合是analyst-curated列表,突出了公司你需要知道的最重要的技术空间。
毛细管中包括生物医学6专家集合,包括可穿戴计算。
可穿戴计算
418件
可穿戴计算是广泛定义为公司开发设备磨损或放置在身体与技术装备,可从可穿戴式医疗器械AR / VR耳机GPS宠物项圈。
医疗设备
8577件
公司发展医疗器械(每IMDRF的“医疗器械”的定义)。包括软件、lab-developed测试(LDTs)和组合产品。*列更新尽可能经常。
糖尿病
2047件
智能家居和消费电子产品
1229件
这个集合包括公司发展智能家居设备、衣物、家电等消费电子产品。
健康监测与诊断
464件
公司开发可穿戴健康监测解决方案(仅人类健康)。公司标记#衣物(*注:这个标签也可能适用于公司这个集合的范围之外)
它的健康
7901件
最新的毛细管生物医学新闻
2022年8月11日
披露:梅塞尔集团报告接收说话和咨询酬金和串联糖尿病护理,Dexcom公司将和毛细管生物医学担任顾问。梅塞尔集团机构接收研究和项目赠款从雅培,β仿生学,,Dexcom公司将Insulet Corp .)、美敦力公司和串联糖尿病护理。请参阅研究对于所有其他作者的相关财务信息披露。主题添加到邮件提醒收到一封电子邮件在发布新文章时请提供您的电子邮件地址来接收电子邮件当张贴新文章。请稍后再试。如果你继续这个问题请联系customerservice@slackinc.com。回到Healio青少年和年轻的成年人与1型糖尿病血糖水平较低的时候感觉也更与他们的糖尿病管理,根据调查结果发表在糖尿病药物。“在青少年和年轻成人糖尿病患者,每日的个人因素,如自尊、健康观念,并计划或希望自己管理糖尿病的所有影响日常血糖,“月桂h·梅塞尔集团博士RN,儿科助理教授芭芭拉·戴维斯中心糖尿病,科罗拉多大学医学院的许茨告诉Healio。“这些日常预测可以被视为新靶点干预帮助支持青少年糖尿病的护理,特别是在帮助激励计划和愿望管理糖尿病早上的第一件事。“梅塞尔集团是一个儿科助理教授芭芭拉·戴维斯中心糖尿病,科罗拉多大学医学院的许茨。梅塞尔集团及其同事进行了一项纵向观察研究的2 88名1型糖尿病青少年和年轻人使用连续血糖监测,胰岛素泵或智能笔,和智能手机来管理他们的糖尿病患者(平均年龄17.6岁; 54% female; 90% white). Participants downloaded CGM and insulin delivery data at the end of the 2-week period to assess time in range, mean sensor glucose and user-initiated boluses. On six randomly selected days, participants completed a 25-item engagement prediction survey to assess biopsychosocial factors that could potentially influence daily engagement with diabetes management. The survey was administered in the morning and participants answered each question on a 4-point Likert scale. At the end of each assessment day, participants completed an end-of-day goal survey on a 5-point Likert scale to assess diabetes management goal attainment. Predictors of time in range, glycemic variability Mean average time in range fluctuated by 16% and mean absolute sensor glucose fluctuated by 30.4 mg/dL per day for each participant (P < .001 for both). The mean absolute change in number of boluses given fluctuated by 2.2 per day (P < .001). Seven questions in the engagement prediction survey were identified as being most predictive of glycemic outcomes. Those item responses predicted 16.7% of time in range variability, 18.6% of mean sensor glucose variability, 2.1% of variance in the number of boluses, 14% of the variability in hyperglycemia response and 28.7% of variability in diabetes management goal attainment. Positive engagement linked to lower glucose levels Participants who reported positively to sleeping longer (beta = –6.6; P < .001), sleeping well the previous night (beta = –12.6; P = .001), planning to manage their diabetes that day (beta = –17.7; P = .004), intending to manage their diabetes (beta = –16.6; P = .008), wanting to manage their diabetes (beta = –15.7; P = .001) and that they were feeling healthy (beta = –22.1; P < .001) were more likely to have lower glucose levels. Conversely, those who said they were too sick to manage their diabetes (beta = 29.1; P < .001) or felt they need extra support for their diabetes management (beta = 11.9; P = .004) had higher morning glucose levels. The cohort estimated they spent a median of 30 minutes caring for their diabetes and a median of 30 minutes thinking about their diabetes each day. The number of minutes thinking about diabetes was associated with the percent of hyperglycemia alerts responded to (P = .035) and perceived goal attainment score (P = .044). The number of minutes caring for diabetes was also positively associated with goal attainment score (P = .022). Time in range was inversely correlated to the number of boluses each day (beta = –0.9; P < .001). “We were most surprised that these factors predicted overall time in range; however, we were not able to explain how often the adolescent gave insulin doses for meals,” Messer said. “Usually, you assume that meal doses of insulin are what improve time in range, so we need to do more work to understand this.” For more information:
毛细管生物医学网络流量
毛细管生物医学排名
毛细管生物医学常见问题(FAQ)
毛细管生物医学是何时成立的?
毛细管生物医药成立于2014年。
毛细管生物医学的总部在哪里?
毛细管生物医学的总部位于8法拉第,欧文。
毛细管生物医学的最新一轮融资是什么?
毛细管生物医学的最新一轮融资收购。
毛细管生物医学筹集了多少钱?
毛细管生物医学筹集了总计4.75美元。
毛细管生物医学的投资者是谁?
毛细管生物医学的投资者包括串联糖尿病护理,利昂娜·m·哈里b·赫尔姆斯利慈善基金,薪水保护计划,质量医疗天使,帕萨迪纳市天使和10。
发现正确的解决方案为您的团队
CB见解德赢体育vwin官方网站科技市场情报平台分析数百万数据点在供应商、产品、合作关系,专利来帮助您的团队发现他们的下一个技术解决方案。